Apellis Pharmaceuticals, Inc.: directors' dealings · United States · SEC (Form 4)

About Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc. (ticker: APLS) is a U.S.-based biopharmaceutical company listed on the Nasdaq in the United States and headquartered in Waltham, Massachusetts. Founded in 2009, the company built its franchise around complement biology, with a specific focus on inhibiting C3, a central protein in the complement cascade. For international investors, Apellis is best viewed as a science-driven commercial biotech: the investment case depends on product uptake, regulatory execution, label expansion, and the durability of its differentiated platform. Apellis’ business today is centered on two marketed pegcetacoplan-based therapies. SYFOVRE is approved for geographic atrophy secondary to age-related macular degeneration, addressing a large ophthalmology market with significant unmet need. EMPAVELI was first approved for paroxysmal nocturnal hemoglobinuria and has since become a broader complement-inhibitor franchise. In July 2025, the U.S. FDA approved EMPAVELI as the first treatment for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years and older, a major expansion into rare kidney diseases. In 2025 and early 2026, Apellis also highlighted longer-term SYFOVRE data and early commercial traction for EMPAVELI in its new renal indications, reinforcing the strategic importance of both assets. From a competitive standpoint, Apellis has established an early-mover position in C3-targeted complement inhibition. That scientific positioning is important because C3 is upstream in the complement pathway, allowing a broader mechanism than more selective downstream approaches. At the same time, the company still carries the typical biotech concentration risk: a small number of core assets, dependence on clinical outcomes and physician adoption, reimbursement dynamics, and ongoing cash burn considerations. Its commercial footprint is primarily in the United States, while international exposure is supported through collaborations and ex-U.S. arrangements, including partnership activity with Sobi in Europe and other markets. Historically, Apellis was incorporated in Delaware in September 2009 and has evolved from a development-stage company into a commercial-stage rare-disease and ophthalmology company. Its headquarters remain in Waltham, Massachusetts, with additional operational presence in the U.S. and abroad. The key recent story for investors is that Apellis is no longer only a pipeline narrative: it now has two marketed products, expanding regulatory reach, and a series of clinical readouts that can move sentiment and financial expectations. In short, APLS is a Nasdaq-listed U.S. biotech with meaningful growth optionality, but also the volatility and event risk that come with a concentrated specialty-pharma model.